The Biden administration has announced the next 15 drugs chosen for Medicare negotiation, marking one of its final acts ...

Like a champion boxer on the ropes, Bristol-Myers Squibb (NYSE: BMY) finds itself in a challenging position. Specifically, ...

Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Bristol-Myers Squibb's recent struggles stem from concerns ... which it acquired as part of its 2019 deal for cancer specialist Celgene. However, the drugmaker's third-quarter 2024 results paint ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

Prior experiences include Vice President, Biology, at Zentalis, Head of Epigenetic Drug Discovery at Bristol-Myers Squibb/Celgene and other leading roles in early drug discovery in oncology.

Prior experiences include Vice President, Biology, at Zentalis, Head of Epigenetic Drug Discovery at Bristol-Myers Squibb/Celgene and other leading roles in early drug discovery in oncology. Brian ...

Bristol-Myers Squibb stock has rebounded strongly in 2024 ... When BMY completed its deal for Celgene in 2020, it inherited several multi-billion dollar selling drug products, such as >$12bn ...